August 30, 2010
Another Strategy, Transdifferentiation, Advanced Cell Technology (ACTC.OB)
August 25, 2010
IND Filed for Chronic Spinal Cord Injury Trial, Neuralstem (NYSE Amex: CUR)
August 19, 2010
Regeneration of Injured Nerves
August 6, 2010
Novel Matrix Predicts Stem Cell Differentiation
July 30, 2010
Cell Lines Replicate Human Skin
July 28, 2010
FDA Filing for Clinical Trials Using ES Cells to Treat Eye Disease, Advanced Cell Technology (ACTC.OB)
July 22, 2010
Regulatory Approval for Adult Stem Cell Products, Mesoblast (ASX: MSB; ADR: MBLTY)
July 20, 2010
Randomized P2 Clinical Trial of Imetelstat in Non-Small Cell Lung Cancer Initiated, Geron (GERN)
July 9, 2010
AlloCure, Stem Cell Therapy for Kidney Failure
July 8, 2010
NIH Lobbies Congress for $500M to Fund Clinical Trials
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.